Effects of cytarabine and various anthracyclins on platelet activation: Characterization of in vitro effects and their possible clinical relevance in acute myelogenous leukemia [PDF]
, 2001 Brynjar Foss +3 more
openalex +1 more source
Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment
Small Science, Volume 5, Issue 4, April 2025.Phagocytosis of “apoptotic tumor cells”, known as efferocytosis, accelerates the formation of an immunosuppressive microenvironment, leading to the detriment of tumor therapy. Blocking this process represents one of the novel approaches for treating tumors.
Gangxing Zhu +9 more
wiley +1 more source
A Rare Case of Langerhans Cell Histiocytosis in the Hard Palate
Turkish Journal of Hematology, 2022 Memiş Hilmi Atay, Seda Gün
doaj +1 more source
A multicentre, open, non‐comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony‐stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation [PDF]
, 2001 Graham Jackson +19 more
openalex +1 more source
ALK+ Anaplastic Large Cell Lymphoma Diagnosed on Paediatric Pericardial Effusion Cytology
Cytopathology, Volume 36, Issue 3, Page 285-289, May 2025.
Connor Hartzell +3 more
wiley +1 more source
British Journal of Haematology, Volume 206, Issue 4, Page 1121-1128, April 2025.Outcomes with olutasidenib appear appreciably better than previous reports of other therapies for blast‐phase myeloproliferative neoplasm (MPN), supporting the role for olutasidenib‐based therapy in mIDH1 AML secondary to MPN. Summary Acute myeloid leukaemia (AML) arising from a myeloproliferative neoplasm (MPN) is more aggressive and less responsive ...
Stéphane De Botton +13 more
wiley +1 more source
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1
British Journal of Haematology, Volume 206, Issue 4, Page 1250-1252, April 2025.Outcomes of myeloproliferative neoplasms (MPN)‐associated acute leukaemias are dismal with conventional therapy. Approximately 20% of MPN‐associated acute leukaemias have mutations in isocitrate dehydrogenase (IDH). Olutasidenib, and inhibitor of IDH1, demonstrates important clinical benefits in MPN‐associated leukaemia with IDH1 mutation.
Keith W. Pratz
wiley +1 more source
Successful Cytoreduction with CAG (cytarabine, Aclarubicin and G-CSF) Therapy in Refractory Acute Myelogenous Leukemia before Allogeneic Stem Cell Transplantation [PDF]
, 2001 Tohru Murayama +7 more
openalex +1 more source
Phase II study of combination human recombinant GM‐CSF with intermediate‐dose cytarabine and mitoxantrone chemotherapy in patients with high‐risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study [PDF]
, 2001 John M. Bennett +12 more
openalex +1 more source
Liposomal cytarabine in cerebrospinal fluid [PDF]
British Journal of Haematology, 2009 Jackie Kenny +4 more
openaire +3 more sources